User menu

Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.

Bibliographic reference Lessire, Sarah ; Sarah, Lessire ; Dincq, Anne-Sophie ; Anne-Sophie, Dincq ; Douxfils, Jonathan ; et. al. Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants.. In: BioMed Research International, Vol. 2014, no.616405, p. 1-14 (2014)
Permanent URL http://hdl.handle.net/2078.1/175791
  1. Journal of Thrombosis and Haemostasis, 111 (2014)
  2. Lassen Michael Rud, Gallus Alexander, Raskob Gary E., Pineo Graham, Chen Dalei, Ramirez Luz Margarita, Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement, 10.1056/nejmoa1006885
  3. Lassen Michael Rud, Raskob Gary E, Gallus Alexander, Pineo Graham, Chen Dalei, Hornick Philip, Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial, 10.1016/s0140-6736(09)62125-5
  4. Lassen Michael Rud, Raskob Gary E., Gallus Alexander, Pineo Graham, Chen Dalei, Portman Ronald J., Apixaban or Enoxaparin for Thromboprophylaxis after Knee Replacement, 10.1056/nejmoa0810773
  5. Eriksson B. I., Dahl O. E., Huo M. H., Kurth A. A., Hantel S., Hermansson K., Schnee J. M., Friedman R. J., , Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*) : A randomised, double-blind, non-inferiority trial, 10.1160/th10-10-0679
  6. ERIKSSON B. I., DAHL O. E., ROSENCHER N., KURTH A. A., VAN DIJK C. N., FROSTICK S. P., KÄLEBO P., CHRISTIANSEN A. V., HANTEL S., HETTIARACHCHI R., SCHNEE J., BÜLLER H. R., , Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, 10.1111/j.1538-7836.2007.02748.x
  7. Eriksson Bengt I, Dahl Ola E, Rosencher Nadia, Kurth Andreas A, van Dijk C Niek, Frostick Simon P, Prins Martin H, Hettiarachchi Rohan, Hantel Stefan, Schnee Janet, Büller Harry R, Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial, 10.1016/s0140-6736(07)61445-7
  8. Eriksson Bengt I., Borris Lars C., Friedman Richard J., Haas Sylvia, Huisman Menno V., Kakkar Ajay K., Bandel Tiemo J., Beckmann Horst, Muehlhofer Eva, Misselwitz Frank, Geerts William, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty, 10.1056/nejmoa0800374
  9. Kakkar Ajay K, Brenner Benjamin, Dahl Ola E, Eriksson Bengt I, Mouret Patrick, Muntz Jim, Soglian Andrea G, Pap Ákos F, Misselwitz Frank, Haas Sylvia, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, 10.1016/s0140-6736(08)60880-6
  10. Lassen Michael R., Ageno Walter, Borris Lars C., Lieberman Jay R., Rosencher Nadia, Bandel Tiemo J., Misselwitz Frank, Turpie Alexander G.G., Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, 10.1056/nejmoa076016
  11. Turpie Alexander GG, Lassen Michael R, Davidson Bruce L, Bauer Kenneth A, Gent Michael, Kwong Louis M, Cushner Fred D, Lotke Paul A, Berkowitz Scott D, Bandel Tiemo J, Benson Alice, Misselwitz Frank, Fisher William D, Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial, 10.1016/s0140-6736(09)60734-0
  12. Granger Christopher B., Alexander John H., McMurray John J.V., Lopes Renato D., Hylek Elaine M., Hanna Michael, Al-Khalidi Hussein R., Ansell Jack, Atar Dan, Avezum Alvaro, Bahit M. Cecilia, Diaz Rafael, Easton J. Donald, Ezekowitz Justin A., Flaker Greg, Garcia David, Geraldes Margarida, Gersh Bernard J., Golitsyn Sergey, Goto Shinya, Hermosillo Antonio G., Hohnloser Stefan H., Horowitz John, Mohan Puneet, Jansky Petr, Lewis Basil S., Lopez-Sendon Jose Luis, Pais Prem, Parkhomenko Alexander, Verheugt Freek W.A., Zhu Jun, Wallentin Lars, Apixaban versus Warfarin in Patients with Atrial Fibrillation, 10.1056/nejmoa1107039
  13. The New England Journal of Medicine, 361, 2674 (2009)
  14. Patel Manesh R., Mahaffey Kenneth W., Garg Jyotsna, Pan Guohua, Singer Daniel E., Hacke Werner, Breithardt Günter, Halperin Jonathan L., Hankey Graeme J., Piccini Jonathan P., Becker Richard C., Nessel Christopher C., Paolini John F., Berkowitz Scott D., Fox Keith A.A., Califf Robert M., , Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, 10.1056/nejmoa1009638
  15. Oral Rivaroxaban for Symptomatic Venous Thromboembolism, 10.1056/nejmoa1007903
  16. , Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism, 10.1056/nejmoa1113572
  17. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial, 10.1016/s0140-6736(09)60738-8
  18. Mega Jessica L., Braunwald Eugene, Wiviott Stephen D., Bassand Jean-Pierre, Bhatt Deepak L., Bode Christoph, Burton Paul, Cohen Marc, Cook-Bruns Nancy, Fox Keith A.A., Goto Shinya, Murphy Sabina A., Plotnikov Alexei N., Schneider David, Sun Xiang, Verheugt Freek W.A., Gibson C. Michael, Rivaroxaban in Patients with a Recent Acute Coronary Syndrome, 10.1056/nejmoa1112277
  19. Hylek Elaine M., Held Claes, Alexander John H., Lopes Renato D., De Caterina Raffaele, Wojdyla Daniel M., Huber Kurt, Jansky Petr, Steg Philippe Gabriel, Hanna Michael, Thomas Laine, Wallentin Lars, Granger Christopher B., Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin, 10.1016/j.jacc.2014.02.549
  20. Harenberg J., Marx S., Dahl O. E., Marder V. J., Schulze A., Wehling M., Weiss C., Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery : , 10.1160/th12-07-0482
  21. Southworth Mary Ross, Reichman Marsha E., Unger Ellis F., Dabigatran and Postmarketing Reports of Bleeding, 10.1056/nejmp1302834
  22. De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., Baigent C., Huber K., Jespersen J., Kristensen S. D., Lip G. Y. H., Morais J., Rasmussen L. H., Siegbahn A., Verheugt F. W. A., Weitz J. I., Vitamin K antagonists in heart disease: Current status and perspectives (Section III) : Position Paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease, 10.1160/th13-06-0443
  23. Poller L., Jespersen J., Ibrahim S., Pattison A., , Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results: a rebuttal, 10.1111/jth.12164
  24. Desai J., Kolb J. M., Weitz J. I., Aisenberg J., Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies : , 10.1160/th13-02-0150
  25. McConeghy Kevin W., Bress Adam, Qato Dima M., Wing Coady, Nutescu Edith A., Evaluation of Dabigatran Bleeding Adverse Reaction Reports in the FDA Adverse Event Reporting System during the First Year of Approval, 10.1002/phar.1415
  26. Eikelboom John W., Wallentin Lars, Connolly Stuart J., Ezekowitz Mike, Healey Jeff S., Oldgren Jonas, Yang Sean, Alings Marco, Kaatz Scott, Hohnloser Stefan H., Diener Hans-Christoph, Franzosi Maria Grazia, Huber Kurt, Reilly Paul, Varrone Jeanne, Yusuf Salim, Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial FibrillationClinical Perspective : An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial, 10.1161/circulationaha.110.004747
  27. Frost Charles, Nepal Sunil, Wang Jessie, Schuster Alan, Byon Wonkyung, Boyd Rebecca A., Yu Zhigang, Shenker Andrew, Barrett Yu Chen, Mosqueda-Garcia Rogelio, LaCreta Frank, Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects : Apixaban multiple dose safety, PK and PD, 10.1111/bcp.12106
  28. Mueck Wolfgang, Stampfuss Jan, Kubitza Dagmar, Becka Michael, Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban, 10.1007/s40262-013-0100-7
  29. Stangier Joachim, Clemens Andreas, Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, 10.1177/1076029609343004
  30. Revue Médicale Suisse, 10, 326 (2014)
  31. Kirley K., Qato D. M., Kornfield R., Stafford R. S., Alexander G. C., National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011, 10.1161/circoutcomes.112.967299
  32. Lim Sueh-li A, Maxwell Ellen, An audit of dabigatran etexilate prescribing in Victoria, 10.5694/mja12.10942
  33. BMJ Open, 3, article e002758 (2013)
  34. Carley Blake, Griesbach Sara, Larson Tonja, Krueger Kori, Assessment of Dabigatran Utilization and Prescribing Patterns for Atrial Fibrillation in a Physician Group Practice Setting, 10.1016/j.amjcard.2013.11.008
  35. Escobar Carlos, Barrios Vivencio, Dabigatran and Bleeding Risk: The Importance of a Correct Prescription, 10.1016/j.jemermed.2013.08.121
  36. Troncoso Amelia, Diogène Eduard, Dabigatran and rivaroxaban prescription for atrial fibrillation in Catalonia, Spain: the need to manage the introduction of new drugs, 10.1007/s00228-013-1593-6
  37. Pfeilschifter Waltraud, Luger Sebastian, Brunkhorst Robert, Lindhoff-Last Edelgard, Foerch Christian, The Gap between Trial Data and Clinical Practice - An Analysis of Case Reports on Bleeding Complications Occurring under Dabigatran and Rivaroxaban Anticoagulation, 10.1159/000352062
  38. BMJ Open, 3, article e002686 (2013)
  39. BMJ Open, 3, article e003343 (2013)
  40. Pharmacotherapy, 32, article 2 (2012)
  41. Patel Jignesh P., Roberts Lara N., Arya Roopen, Anticoagulating obese patients in the modern era : Review, 10.1111/j.1365-2141.2011.08826.x
  42. Kubitza Dagmar, Becka Michael, Zuehlsdorf Michael, Mueck Wolfgang, Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59-7939) in Healthy Subjects, 10.1177/0091270006296058
  43. Mueck Wolfgang, Eriksson Bengt I, Bauer Kenneth A, Borris Lars, Dahl Ola E, Fisher William D, Gent Michael, Haas Sylvia, Huisman Menno V, Kakkar Ajay K, Kälebo Peter, Kwong Louis M, Misselwitz Frank, Turpie Alexander G G, Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery : , 10.2165/00003088-200847030-00006
  44. Upreti Vijay V., Wang Jessie, Barrett Yu Chen, Byon Wonkyung, Boyd Rebecca A., Pursley Janice, LaCreta Frank P., Frost Charles E., Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects : Effect of extremes of body weight on the PK/PD of apixaban, 10.1111/bcp.12114
  45. Stangier Joachim, Stähle Hildegard, Rathgen Karin, Roth Willy, Shakeri-Nejad Kasra, Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment, 10.1177/0091270008324179
  46. Graff Jochen, Harder Sebastian, Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment, 10.1007/s40262-013-0034-0
  47. Kubitza Dagmar, Roth Angelika, Becka Michael, Alatrach Abir, Halabi Atef, Hinrichsen Holger, Mueck Wolfgang, Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor : Rivaroxaban pharmacokinetics and pharmacodynamics in hepatic impairment, 10.1111/bcp.12054
  48. Clinical Pharmacology & Therapeutics, 85, S34 (2009)
  49. Heidbuchel Hein, Verhamme Peter, Alings Marco, Antz Matthias, Hacke Werner, Oldgren Jonas, Sinnaeve Peter, Camm A. John, Kirchhof Paulus, European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, 10.1093/europace/eut083
  50. Nutescu Edith, Chuatrisorn Ittiporn, Hellenbart Erika, Drug and dietary interactions of warfarin and novel oral anticoagulants: an update, 10.1007/s11239-011-0561-1
  51. Walenga J. M., Adiguzel C., Drug and dietary interactions of the new and emerging oral anticoagulants : Drug interactions of new oral anticoagulants, 10.1111/j.1742-1241.2009.02286.x
  52. RODEGHIERO F., TOSETTO A., ABSHIRE T., ARNOLD D. M., COLLER B., JAMES P., NEUNERT C., LILLICRAP D., , ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders : ISTH/SSC bleeding assessment tool, 10.1111/j.1538-7836.2010.03975.x
  53. Apostolakis S., Lane D. A., Buller H., Lip G. Y. H., Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: The AMADEUS trial : , 10.1160/th13-07-0552
  54. Burgess S., Crown N., Louzada M. L., Dresser G., Kim R. B., Lazo-Langner A., Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin, 10.1111/jth.12352
  55. Reilly Paul A., Lehr Thorsten, Haertter Sebastian, Connolly Stuart J., Yusuf Salim, Eikelboom John W., Ezekowitz Michael D., Nehmiz Gerhard, Wang Susan, Wallentin Lars, The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients, 10.1016/j.jacc.2013.07.104
  56. ten Cate H., Monitoring new oral anticoagulants, managing thrombosis, or both? : , 10.1160/th12-03-0130
  57. LIESENFELD K.-H., LEHR T., DANSIRIKUL C., REILLY P. A., CONNOLLY S. J., EZEKOWITZ M. D., YUSUF S., WALLENTIN L., HAERTTER S., STAAB A., Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial : Population pharmacokinetics of dabigatran>, 10.1111/j.1538-7836.2011.04498.x
  58. Freyburger Geneviève, Macouillard Gérard, Labrouche Sylvie, Sztark François, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement, 10.1016/j.thromres.2011.01.001
  59. Thrombosis Journal, 11, article 22 (2013)
  60. Drug Development Research, 74, article 7 (2013)
  61. Thrombosis Journal, 11, article 8 (2013)
  62. Baglin Trevor, Keeling David, Kitchen Steve, Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology, 10.1111/bjh.12052
  63. Turpie A. G. G., Kreutz R., Llau J., Norrving B., Haas S., Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor : , 10.1160/th12-03-0209
  64. Baglin T., Hillarp A., Tripodi A., Elalamy I., Buller H., Ageno W., Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 10.1111/jth.12149
  65. Pernod Gilles, Albaladejo Pierre, Godier Anne, Samama Charles M., Susen Sophie, Gruel Yves, Blais Normand, Fontana Pierre, Cohen Ariel, Llau Juan V., Rosencher Nadia, Schved Jean-François, de Maistre Emmanuel, Samama Meyer M., Mismetti Patrick, Sié Pierre, Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) – March 2013, 10.1016/j.acvd.2013.04.009
  66. Barrett Y. C., Wang J., Song Y., Pursley J., Wastall P., Wright R., LaCreta F., Frost C., A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects : , 10.1160/th11-09-0634
  67. Douxfils J., Mullier F., Robert S., Chatelain C., Chatelain B., Dogné J.-M., Impact of dabigatran on a large panel of routine or specific coagulation assays : Laboratory recommendations for monitoring of dabigatran etexilate, 10.1160/th11-11-0804
  68. Douxfils J., Chatelain C., Chatelain B., Dogné J.-M., Mullier F., Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide : , 10.1160/th12-12-0898
  69. Douxfils J., Tamigniau A., Chatelain B., Chatelain C., Wallemacq P., Dogné J.-M., Mullier F., Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban : , 10.1160/th13-04-0274
  70. Huisman M. V., Lip G. Y. H., Diener H.-C., Brueckmann M., van Ryn J., Clemens A., Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice : , 10.1160/th11-10-0718
  71. Baron Todd H., Kamath Patrick S., McBane Robert D., Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures, 10.1056/nejmra1206531
  72. Kozek-Langenecker Sibylle A., Perioperative Management Issues of Direct Oral Anticoagulants, 10.1053/j.seminhematol.2014.02.001
  73. Liew Aaron, Douketis James, Perioperative management of patients who are receiving a novel oral anticoagulant, 10.1007/s11739-013-0963-5
  74. Sié Pierre, Samama Charles M., Godier Anne, Rosencher Nadia, Steib Annick, Llau Juan V., Van der Linden Philippe, Pernod Gilles, Lecompte Thomas, Gouin-Thibault Isabelle, Albaladejo Pierre, Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemostasis, 10.1016/j.acvd.2011.09.001
  75. Spyropoulos A. C., Douketis J. D., How I treat anticoagulated patients undergoing an elective procedure or surgery, 10.1182/blood-2012-06-415943
  76. Beyer-Westendorf J., Gelbricht V., Forster K., Ebertz F., Kohler C., Werth S., Kuhlisch E., Stange T., Thieme C., Daschkow K., Weiss N., Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry, 10.1093/eurheartj/eht557
  77. Gogarten Wiebke, Vandermeulen Erik, Van Aken Hugo, Kozek Sibylle, Llau Juan V, Samama Charles M, Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology : , 10.1097/eja.0b013e32833f6f6f
  78. Levy Jerrold H., Faraoni David, Spring Jenna L., Douketis James D., Samama Charles M., Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting : , 10.1097/aln.0b013e318289bcba
  79. Llau Juan V, Ferrandis Raquel, New anticoagulants and regional anesthesia : , 10.1097/aco.0b013e32832eb8ab
  80. Rosencher N., Bonnet M.-P., Sessler D. I., Selected new antithrombotic agents and neuraxial anaesthesia for major orthopaedic surgery: management strategies : Anaesthesia and antithrombotic agents, 10.1111/j.1365-2044.2007.05195.x
  81. Kaatz Scott, Crowther Mark, Reversal of target-specific oral anticoagulants, 10.1007/s11239-013-0923-y
  82. Kaatz Scott, Kouides Peter A., Garcia David A., Spyropolous Alex C., Crowther Mark, Douketis Jim D., Chan Anthony K. C., James Andra, Moll Stephan, Ortel Thomas L., Van Cott Elizabeth M., Ansell Jack, Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, 10.1002/ajh.23202
  83. Siegal D. M., Garcia D. A., Crowther M. A., How I treat target-specific oral anticoagulant-associated bleeding, 10.1182/blood-2013-09-529784
  84. Majeed A., Hwang H.-G., Connolly S. J., Eikelboom J. W., Ezekowitz M. D., Wallentin L., Brueckmann M., Fraessdorf M., Yusuf S., Schulman S., Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin, 10.1161/circulationaha.113.002332
  85. Thrombosis and Haemostasis, 111, 189 (2014)
  86. Piccini J. P., Garg J., Patel M. R., Lokhnygina Y., Goodman S. G., Becker R. C., Berkowitz S. D., Breithardt G., Hacke W., Halperin J. L., Hankey G. J., Nessel C. C., Mahaffey K. W., Singer D. E., Califf R. M., Fox K. A. A., , Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial, 10.1093/eurheartj/ehu083
  87. van Ryn J., Stangier J., Haertter S., Liesenfeld K.-H., Wienen W., Feuring M., Clemens A., Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity : , 10.1160/th09-11-0758
  88. Annals of Pharmacotherapy, 46, article e21 (2012)
  89. Warkentin T. E., Margetts P., Connolly S. J., Lamy A., Ricci C., Eikelboom J. W., Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding, 10.1182/blood-2011-11-393587
  90. Critical Care, 18, article r27 (2014)
  91. Lu Genmin, DeGuzman Francis R, Hollenbach Stanley J, Karbarz Mark J, Abe Keith, Lee Gail, Luan Peng, Hutchaleelaha Athiwat, Inagaki Mayuko, Conley Pamela B, Phillips David R, Sinha Uma, A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, 10.1038/nm.3102
  92. Thrombosis Journal, 11, article 27 (2013)
  93. Majeed Ammar, Schulman Sam, Bleeding and antidotes in new oral anticoagulants, 10.1016/j.beha.2013.07.001